-
1. Trial Name : FOCUS Started on 2021
Sponsor: Novo Nordisk
Title: Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes.
Medicine: Semaglutide/Placebo weekly once, Trial duration 5 years
-
2.Trial Name : REDEFINE 2 started on 2022
Sponsor: Novo Nordisk
Title: Efficacy and safety of cagrilintide s.c 2.4 mg in combination with semaglutide s.c 2.4 mg (cagriSema s.c 2.4 mg) once weekly in participants with overweight or obesity and type 2 diabetes.
-
3.Trial Name: TRIUMPH -1 Started on 2023
Sponsor: Eli Lilly
Title : A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once weekly
participants without Type 2 Diabetes who have Obesity or Overweight: A randomized, Double-Blind, Placebo-Controlled Trial.
Medicine: Retatrutide / Placebo weekly once, trial duration one and half years.
Indication: Obesity
-
4. Trial Name : REIMAGINE -4 Started on 2024
Sponsor: Novo Nordisk
Title : Efficacy and Safety of Co-administrated Cagrilintie and Semaflutide ( CagriSema) 2.4 mg/2.4 mg s.c Once weekly versus Tirzepatide 15mg s.c once weekly in participants with Type 2 Diabetes inadequately controlled on Metformin with or without on SGLT2 inhibitor.
Medicine: CagriSema / Tirzepatide weekly oncem trial duration one and half years.
Indication : Obesity / Type 2 diabtes
